Our proprietary FOCO-CAR technology platform adheres to four core principles: Fast, Optimized, Cost-down, and Organized, aiming to systematically achieve efficacy persistency, cost reduction, and process robustness.

Our FOCO-CAR process provides a comprehensive suite of solutions which shortens in vitro expansion and vein-to-vein time, and achieves persistent antitumor activity. In addition, the process effectively manages the manufacturing cost by promoting the domestic substitution of key materials, simplifying process operations, and synergizing with our closed linear production model.

Our iMAGIC platform (Innovative MxV-G-LV Activated and Generated in vivo CAR-T) is a proprietary lentiviral-based in vivo CAR-T technology designed to address key limitations of conventional autologous CAR-T therapies, including complex manufacturing requirements, extended vein-to-vein timelines, and high costs. 

The platform incorporates a detargeted MxV glycoprotein (MxV-G), which is optimized through artificial intelligence (AI) driven design approaches. In combination with a proprietary T cell–targeting module (TCM), the Imagic platform enabling selective activation and transduction of T cells directly in vivo while reducing off-target gene delivery to non-T cells.

Another major challenge currently associated with CAR-T therapies for solid tumors is on-target off-tumor toxicity. In solid tumors, there is a scarcity of tumor-specific targets that are not shared with critical, healthy tissues. In the absence of tumor-specific antigens for solid tumors, CAR-T cell therapies for solid tumors have employed CARs directed to tumor-associated antigens that are also expressed to some extent in normal tissues, and the risk of on-target off-tumor toxicity has been observed in clinical trials of CAR-T therapies for especially solid tumors. 

To address this, our Peri Cruiser® platform is designed to limit CAR-T cell infiltration into normal tissues by modulating key adhesion and trafficking pathways. Specifically, a triple knockdown of CD11a, CD49d, and PSGL1, molecules critical for T-cell adhesion and tissue migration, was developed to reduce non-tumor tissue engagement while preserving antitumor cytotoxicity, thereby improving the therapeutic window of CAR-T cells.

The clinical efficacy of CAR-T cell therapies in solid tumors has been constrained by pronounced tumor antigen heterogeneity, which is characterized by the expression of a single tumor-associated antigen may be heterogeneous, dynamic, or downregulated under therapeutic pressure, resulting in incomplete tumor coverage and antigen escape. 

NKG2D ligands (“NKG2DLs”) represent a class of stress-induced molecules that are broadly upregulated across a wide range of solid and hematologic malignancies and suppressive cells within hostile tumor niches, while generally exhibiting low or absent expression in normal tissues. Their expression is driven by oncogenic stress, DNA damage responses, and inflammatory signaling, making NKG2DLs complementary targets to conventional tumor-associated antigens for addressing both antigen heterogeneity of tumor. 

Building on this biological rationale, our Synthetic NKG2D Receptor (“SNR”) platform is designed to enable CAR-T cells to simultaneously engage NKG2D ligands and a second tumor-associated antigen through co-expression of a SNR module alongside a conventional CAR construct. The SNR module incorporates extracellular domain of NKG2D and intracellular signaling domains derived from DAP10 and DAP12, which could provide complementary co-stimulatory signals that enhance T cell activation, metabolic fitness, and persistence, while mitigating premature exhaustion.

Another major challenge currently associated with CAR-T therapies for solid tumors is the limited infiltration of CAR-T cells into the tumor tissue and the poor persistence of CAR-T cells, with limited long-term expansion and efficacy. Our T-Booster technology platform is designed to address limitations observed with CAR-T cell therapies in solid tumors, including restricted tumor infiltration, and suboptimal in vivo expansion. 

The T-Booster technology platform consists of an engineered dendritic cell vaccine expressing a tumor-associated antigen together with selected immunostimulatory molecules, including interleukin-12 (IL-12) and the chemokine CXCL9 T-Booster is designed for use in combination with CAR-T therapies. By leveraging the antigen presenting and immune-modulatory functions of DCs, the platform is intended to promote recruitment of CAR-T cells to tumor sites, and support sustained T-cell activity and persistence.

SolidGuard platform is designed to alleviate the inhibition of antitumor immune response carried out by immunosuppressive Regulatory T cells (Tregs). By releasing immunosuppressive cytokines like TGF-β, Tregs can disrupt the normal endogenous immune response (dendritic cells, T cells etc.) by suppressing the maturation of antigen presenting cells (APCs) and the delivery of the co-stimulatory signals, as well as the proliferation and functionalities of the CAR-T cells. 

This platform is designed to simultaneously target tumor-associated antigens (TAAs) and an undisclosed target, which is highly expressed on the tumor infiltrated Treg cells, with the goal of reducing local Treg-mediated TME immunosuppression while inducing CAR-T cell proliferation and cytotoxicity.